Journal of Neoplasms

 

The "Journal of Neoplasms" stands as a premier Open Access & Peer-Reviewed publication, devoted to deepening the understanding and knowledge of neoplastic diseases. Recognized as a leading authority in the field, our journal is dedicated to providing cutting-edge research and insights to a global audience, acting as a reliable resource for professionals and researchers in oncology and related disciplines.

 

The heartbeat of our journal is oncology research, spanning a broad spectrum of topics including cancer biology, tumor pathology, molecular mechanisms, and therapeutic advancements in the realm of neoplasms. The journal serves as a platform for highlighting innovative approaches and advancements in oncology. We showcase studies that significantly contribute to the understanding, diagnosis, and treatment of neoplastic diseases.

 

DOI: 2639-1716

ISSN: 10.14302/issn.2639-1716

Review: 09 days from the submission time.

Acceptance rate: 54%

Submission to a final decision: 12 days

Acceptance to publication: 3 days

Impact Factor: 2.963

Indexing: The articles appear in a wide range of abstracting and indexing databases, and are covered by numerous other services that aid discovery and access.

Article Processing Charges: JN is a self-supporting journal and does not receive funding from any institution/government. Hence, the operation of the journal is supported by the processing fees received from authors.

 

Types of Manuscript submissions: The author can choose any of the following submission types.

 

 

 

 

Revelation: OpenAccess is a great way to connect scientists and the public. It is not only beneficial to the public, but also to scientists who publish because the more people know and discuss scientific finds, the greater its impact becomes.

 

Various journals: Do not hesitate to acknowledge us if your research scope varies from the mentioned journal. We have ample journals dealing with various subjects. For your reference, I’m providing the complete journals list.

 

Contact: Editorial inquiries should be directed to [email protected]

 

Thank you for joining us in advance!